Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Leukemia, Myelogenous, Chronic, BCR-ABL Positive × pertuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 9 Neoplasms 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 Endometrial Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 7 fludarabine phosphate 6 fludarabine 6 Whole-Body Irradiation 5 Mycophenolic Acid 4 asciminib 3 Mesna 3 Melphalan 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Filgrastim 3 Dasatinib 3 nilotinib 2 bosutinib 2 Tacrolimus 2 Stem Cell Transplantation 2 Cyclosporine 2 Busulfan 2 Bone Marrow Transplantation 2 venetoclax 1 treosulfan 1 thymoglobulin 1 ponatinib 1 blinatumomab 1 aldesleukin 1 Thiotepa 1 Succimer 1 Peripheral Blood Stem Cell Transplantation 1 Pentetic Acid 1 Patient Reported Outcome Measures 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡